Erratum: Metastatic neuroblastoma cancer stem cells exhibit flexible plasticity and adaptive stemness signaling (Stem Cell Research and Therapy (2015) 6 (400) DOI 10.1186/s13287-015-0002-8);Metastatic neuroblastoma cancer stem cells exhibit flexible plasticity and adaptive stemness signaling

Stem Cell Research and Therapy

Volumn 6, Issue 1, 2015, Pages

  Pandian, Vijayabaskar ^a   Ramraj, Satishkumar ^a   Khan, Faizan H ^a   Azim, Tasfia ^a   Aravindan, Natarajan ^a  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; CXCL2 CHEMOKINE; EPIDERMAL GROWTH FACTOR RECEPTOR; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MYC PROTEIN; NERVE CELL ADHESION MOLECULE; NOTCH1 RECEPTOR; TRANSCRIPTION FACTOR NANOG; TRANSCRIPTION FACTOR RELA; TRANSCRIPTION FACTOR SOX2; TRANSCRIPTOME; UVOMORULIN; ABC TRANSPORTER; ABCG2 PROTEIN, HUMAN; CADHERIN; I KAPPA B KINASE; RELA PROTEIN, HUMAN; TUMOR PROTEIN;

ANCHORAGE INDEPENDENT GROWTH; ARTICLE; CANCER CELL; CANCER STEM CELL; CELL CLONE; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DRUG RESISTANCE; EPITHELIAL MESENCHYMAL TRANSITION; EX VIVO STUDY; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; METASTASIS; METASTATIC SITE DERIVED AGGRESSIVE CELL; NEUROBLASTOMA; NEUROBLASTOMA CELL; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; STEM CELL EXPANSION; STEM CELL NICHE; CELL PLASTICITY; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MULTICELLULAR SPHEROID; PATHOLOGY; PHYSIOLOGY; TUMOR CELL CULTURE; TUMOR RECURRENCE;

ATP BINDING CASSETTE TRANSPORTER, SUB-FAMILY G, MEMBER 2; ATP-BINDING CASSETTE TRANSPORTERS; CADHERINS; CELL PLASTICITY; CELL PROLIFERATION; EPITHELIAL-MESENCHYMAL TRANSITION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; I-KAPPA B KINASE; NEOPLASM METASTASIS; NEOPLASM PROTEINS; NEOPLASM RECURRENCE, LOCAL; NEOPLASTIC STEM CELLS; NEUROBLASTOMA; NF-KAPPA B P50 SUBUNIT; SIGNAL TRANSDUCTION; SPHEROIDS, CELLULAR; TRANSCRIPTION FACTOR RELA; TUMOR CELLS, CULTURED;

EID: 84927560173     PISSN: None     EISSN: 17576512     Source Type: Journal    
DOI: 10.1186/s13287-016-0291-6     Document Type: Erratum

References (55)

1. Marc TG, Gurney JG, Smith MA, Olshan AF. Sympathetic nervous system tumors. In: Cancer incidence and survival among children and adolescents: United States SEER Program 1975-1995. Bethesda, MD: National Cancer Institute; 1999. p. 65-72. NIH Pub. No. 99-4649(ICCC IV).
2. Gurney JG, Smith MA, Ross JA. Cancer among infants. In: Cancer incidence and survival among children and adolescents: United States SEER Program 1975-1995. Bethesda, MD: National Cancer Institute; 1999. p. 149-56. NIH Pub. No. 99-4649 (XII).
3. Fernandes KJ, Miller FD. Isolation, expansion, and differentiation of mouse skin-derived precursors. Methods Mol Biol. 2009;482:159-70.
4. Toma JG, McKenzie IA, Bagli D, Miller FD. Isolation and characterization of multipotent skin-derived precursors from human skin. Stem Cells. 2005;23:727-37.
5. Shimada H, Chatten J, Newton Jr WA, Sachs N, Hamoudi AB, Chiba T, et al. Histopathologic prognostic factors in neuroblastic tumors: definition of subtypes of ganglioneuroblastoma and an age-linked classification of neuroblastomas. J Natl Cancer Inst. 1984;73:405-16.
6. Mahller YY, Williams JP, Baird WH, Mitton B, Grossheim J, Saeki Y, et al. Neuroblastoma cell lines contain pluripotent tumor initiating cells that are susceptible to a targeted oncolytic virus. PLoS One. 2009;4:e4235.
7. DeClerck YA, Bomann ET, Spengler BA, Biedler JL. Differential collagen biosynthesis by human neuroblastoma cell variants. Cancer Res. 1987;47:6505-10.
8. Tsokos M, Scarpa S, Ross RA, Triche TJ. Differentiation of human neuroblastoma recapitulates neural crest development. Study of morphology, neurotransmitter enzymes, and extracellular matrix proteins. Am J Pathol. 1987;128:484-96.
9. Walton JD, Kattan DR, Thomas SK, Spengler BA, Guo HF, Biedler JL, et al. Characteristics of stem cells from human neuroblastoma cell lines and in tumors. Neoplasia. 2004;6:838-45.
10. Ross RA, Spengler BA. Human neuroblastoma stem cells. Semin Cancer Biol. 2007;17:241-7.
11. Hirschmann-Jax C, Foster AE, Wulf GG, Nuchtern JG, Jax TW, Gobel U, et al. A distinct "side population" of cells with high drug efflux capacity in human tumor cells. Proc Natl Acad Sci U S A. 2004;101:14228-33.
12. Islam MO, Kanemura Y, Tajria J, Mori H, Kobayashi S, Hara M, et al. Functional expression of ABCG2 transporter in human neural stem/progenitor cells. Neurosci Res. 2005;52:75-82.
13. Thomas SK, Messam CA, Spengler BA, Biedler JL, Ross RA. Nestin is a potential mediator of malignancy in human neuroblastoma cells. J Biol Chem. 2004;279:27994-9.
14. McGinn CJ, Kinsella TJ. The experimental and clinical rationale for the use of S-phase-specific radiosensitizers to overcome tumor cell repopulation. Semin Oncol. 1992;19:21-8.
15. Yu F, Sim AC, Li C, Li Y, Zhao X, Wang DY, et al. Identification of a subpopulation of nasopharyngeal carcinoma cells with cancer stem-like cell properties by high aldehyde dehydrogenase activity. Laryngoscope. 2013;123:1903-11.
16. Vu NB, Nguyen TT, Tran LC, Do CD, Nguyen BH, Phan NK, et al. Doxorubicin and 5-fluorouracil resistant hepatic cancer cells demonstrate stem-like properties. Cytotechnology. 2013;65:491-503.
17. Torigoe T, Hirohashi Y, Yasuda K, Sato N. Constitutive expression and activation of stress response genes in cancer stem-like cells/tumour initiating cells: potent targets for cancer stem cell therapy. Int J Hyperthermia. 2013;29:436-41.
18. He K, Xu T, Xu Y, Ring A, Kahn M, Goldkorn A. Cancer cells acquire a drug resistant, highly tumorigenic, cancer stem-like phenotype through modulation of the PI3K/Akt/beta-catenin/CBP pathway. Int J Cancer. 2014;134:43-54.
19. Hardin H, Montemayor-Garcia C, Lloyd RV. Thyroid cancer stem-like cells and epithelial-mesenchymal transition in thyroid cancers. Hum Pathol. 2013;44:1707-13.
20. Hu X, Ghisolfi L, Keates AC, Zhang J, Xiang S, Lee DK, et al. Induction of cancer cell stemness by chemotherapy. Cell Cycle. 2012;11:2691-8.
21. Germann M, Wetterwald A, Guzman-Ramirez N, van der Pluijm G, Culig Z, Cecchini MG, et al. Stem-like cells with luminal progenitor phenotype survive castration in human prostate cancer. Stem Cells. 2012;30:1076-86.
22. Maris JM, Hogarty MD, Bagatell R, Cohn SL. Neuroblastoma. Lancet. 2007;369:2106-20.
23. Morgenstern DA, Baruchel S, Irwin MS. Current and future strategies for relapsed neuroblastoma: challenges on the road to precision therapy. J Ped Hematol Oncol. 2013;35:337-47.
24. Matthay KK, Reynolds CP, Seeger RC, Shimada H, Adkins ES, Haas-Kogan D, et al. Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study. J Clin Oncol. 2009;27:1007-13.
25. Cole KA, Maris JM. New strategies in refractory and recurrent neuroblastoma: translational opportunities to impact patient outcome. Clin Cancer Res. 2012;18:2423-8.
26. Santana VM, Furman WL, McGregor LM, Billups CA. Disease control intervals in high-risk neuroblastoma. Cancer. 2008;112:2796-801.
27. Simon T, Berthold F, Borkhardt A, Kremens B, De Carolis B, Hero B. Treatment and outcomes of patients with relapsed, high-risk neuroblastoma: results of German trials. Pediatr Blood Cancer. 2011;56:578-83.
28. Lau L, Tai D, Weitzman S, Grant R, Baruchel S, Malkin D. Factors influencing survival in children with recurrent neuroblastoma. J Pediatr Hematol Oncol. 2004;26:227-32.
29. Smith MA, Seibel NL, Altekruse SF, Ries LA, Melbert DL, O'Leary M, et al. Outcomes for children and adolescents with cancer: challenges for the twenty-first century. J Clin Oncol. 2010;28:2625-34.
30. Berthold F, Hero B, Breu H, Christiansen H, Erttmann R, Gnekow A, et al. The recurrence patterns of stages I, II and III neuroblastoma: experience with 77 relapsing patients. Ann Oncol. 1996;7:183-7.
31. Garaventa A, Parodi S, De Bernardi B, Dau D, Manzitti C, Conte M, et al. Outcome of children with neuroblastoma after progression or relapse. A retrospective study of the Italian neuroblastoma registry. Eur J Cancer. 2009;45:2835-42.
32. Weiss B, Vora A, Huberty J, Hawkins RA, Matthay KK. Secondary myelodysplastic syndrome and leukemia following 131I-metaiodobenzylguanidine therapy for relapsed neuroblastoma. J Pediatr Hematol Oncol. 2003;25:543-7.
33. Sieber-Blum M, Hu Y. Mouse epidermal neural crest stem cell (EPI-NCSC) cultures. J Vis Exp. 2008;15:772.
34. Park IH, Zhao R, West JA, Yabuuchi A, Huo H, Ince TA, et al. Reprogramming of human somatic cells to pluripotency with defined factors. Nature. 2008;451:141-6.
35. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006;126:663-76.
36. Yu J, Hu K, Smuga-Otto K, Tian S, Stewart R, Slukvin II, et al. Human induced pluripotent stem cells free of vector and transgene sequences. Science. 2009;324:797-801.
37. Almanaa TN, Geusz ME, Jamasbi RJ. A new method for identifying stem-like cells in esophageal cancer cell lines. J Cancer. 2013;4:536-48.
38. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med. 1997;3:730-7.
39. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A. 2003;100:3983-8.
40. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, et al. Identification of human brain tumour initiating cells. Nature. 2004;432:396-401.
41. O'Brien CA, Pollett A, Gallinger S, Dick JE. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature. 2007;445:106-10.
42. Liu QX, Tang JY, Cai JY, Yin MZ, Li BS. The cultivation and identification of tumor stem cells from neuroblastoma derived tumor spheres. Chin J Cancer. 2010;29:1012-7.
43. Veeraraghavan J, Natarajan M, Aravindan S, Herman TS, Aravindan N. Radiation-triggered tumor necrosis factor (TNF) alpha-NFkappaB cross-signaling favors survival advantage in human neuroblastoma cells. J Biol Chem. 2011;286:21588-600.
44. Aravindan N, Thomas Jr CR, Aravindan S, Mohan AS, Veeraraghavan J, Natarajan M. Irreversible EGFR inhibitor EKB-569 targets low-LET gamma-radiation-triggered rel orchestration and potentiates cell death in squamous cell carcinoma. PLoS One. 2011;6:e29705.
45. Veeraraghavan J, Natarajan M, Herman TS, Aravindan N. Low-dose gamma-radiation-induced oxidative stress response in mouse brain and gut: regulation by NFkappaB-MnSOD cross-signaling. Mutat Res. 2011;718:44-55.
46. Natarajan M, Aravindan N, Meltz ML, Herman TS. Post-translational modification of I-kappa B alpha activates NF-kappa B in human monocytes exposed to 56Fe ions. Radiat Environ Biophys. 2002;41:139-44.
47. London WB, Castel V, Monclair T, Ambros PF, Pearson AD, Cohn SL, et al. Clinical and biologic features predictive of survival after relapse of neuroblastoma: a report from the International Neuroblastoma Risk Group project. J Clin Oncol. 2011;29:3286-92.
48. Kamijo T. Role of stemness-related molecules in neuroblastoma. Pediatr Res. 2012;71:511-5.
49. Kreissman SG, Seeger RC, Matthay KK, London WB, Sposto R, Grupp SA, et al. Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial. Lancet Oncol. 2013;14:999-1008.
50. Kamijo T, Nakagawara A. Molecular and genetic bases of neuroblastoma. Int J Clin Oncol. 2012;17:190-5.
51. Khalil MA, Hrabeta J, Cipro S, Stiborova M, Vicha A, Eckschlager T. Neuroblastoma stem cells - mechanisms of chemoresistance and histone deacetylase inhibitors. Neoplasma. 2012;59:737-46.
52. Marjanovic ND, Weinberg RA, Chaffer CL. Cell plasticity and heterogeneity in cancer. Clin Chem. 2013;59:168-79.
53. Meacham CE, Morrison SJ. Tumour heterogeneity and cancer cell plasticity. Nature. 2013;501:328-37.
54. Chakrabarti L, Abou-Antoun T, Vukmanovic S, Sandler AD. Reversible adaptive plasticity: a mechanism for neuroblastoma cell heterogeneity and chemo-resistance. Front Oncol. 2012;2:82.
55. Chakrabarti L, Wang BD, Lee NH, Sandler AD. A mechanism linking Id2-TGFbeta crosstalk to reversible adaptive plasticity in neuroblastoma. PLoS One. 2013;8:e83521.